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Background: Guidelines recommend that patients with atrial fibrillation (AF) are involved in oral
anticoagulant (OAC) treatment decisions. Understanding which OAC attributes AF patients
value most could help optimize treatment.
Objective: To assess the relationship between patient’s stroke knowledge and their preferences
for specific OAC attributes.
Methods: A cross-sectional online survey was conducted in patients with nonvalvular AF taking
an OAC for stroke prevention in the United States, Canada, Germany, France, and Japan.
Patients were asked about their stroke knowledge, perception of the seriousness of AF and con-
cern about stroke, and to rank 7 OAC attributes in order of importance. A conjoint analysis was
performed to determine the inherent value of 4 attributes.
Results: In total, 937 patients (mean age [standard deviation] 54.3 [16.6] years; 37.1% female)
participated. Of these, 19.5%, 27.9%, and 29.8% had good, moderate, and low stroke knowl-
edge, respectively; 22.8% had no stroke knowledge. Overall, 39.4% of patients (47.5% with
good stroke knowledge) perceived AF as very/extremely serious. The OAC attribute ranked as
most important was stroke prevention followed by major bleeding risk, other side effects, dosing
frequency, antidote availability, dietary restrictions, and use with/without food. In the conjoint
analysis, stroke risk reduction was the most valued property, followed by reduction in major
bleeding risk, less frequent administration, and administration with/without food. Preferences
did not differ with level of stroke knowledge, perception of seriousness of AF, concern of
stroke, or medication burden.
Conclusions:Most AF patients consider efficacy and safety to be the most important OAC attri-
butes, whereas dosing frequency was deemed as less important.
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1 | INTRODUCTION
Current treatment guidelines for stroke prevention in patients with
atrial fibrillation (AF) recommend patient involvement in decisions1–3
to improve adherence to medication and clinical outcomes.1,4 How-
ever, many AF patients have a poor understanding of the condition
and limited knowledge regarding stroke and oral anticoagulants
(OACs).4–9 Many studies of stroke knowledge have been conducted in
the general population10–15 and in individuals with a variety of stroke
risk factors16 rather than AF patients specifically, and to our knowl-
edge, the relationship between stroke knowledge and OAC prefer-
ences in the AF population has not been assessed.
A better understanding of the patient viewpoint, and the extent
to which patients value individual OAC attributes, could help physi-
cians to decide on the most appropriate treatment in collaboration
with the patient, as recommended by the guidelines.
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The objective of our study was to assess the relationship between
patients' stroke knowledge and their preferences for specific OAC
attributes, using 2 methods: (1) a ranking exercise and (2) a choice-
based conjoint analysis. The study also assessed whether patient pref-
erences differed with respect to medication burden, perception of
seriousness of AF, concern about stroke, and whether patients had a
recent or established AF diagnosis, with or without a recent stroke.
2 | METHODS
A cross-sectional, multinational (the United States, Canada, Ger-
many, France, and Japan) survey was conducted in adults (≥18 years
old) with nonvalvular AF receiving an OAC for stroke prevention.
Patients were recruited through consumer panels, or by telephone
or face-to-face contact resulting from referrals from physicians,
nurses, or other patients, or from patient associations or social
media. Patients were stratified into 3 groups: newly diagnosed AF
(within the previous 6 months [12 months in Japan]) without recent
stroke; established AF (diagnosed between 7 and 24 months previ-
ously [1–3 years previously in Japan]) without recent stroke; and AF
(diagnosed at any time) with a recent stroke (within the past
6 months).
Patients completed a 30-minute online questionnaire on stroke
knowledge, perception of AF and stroke, current medication burden,
and views on OACs. Three open-ended questions on etiology, stroke
symptoms, and risk factors were used to categorize patients as having
a good, moderate, or low level of stroke knowledge, or no stroke
knowledge, using a predefined scoring system (see Supporting Table 1
in the online version of this article).
Patients were asked how many different medications they took
daily, the daily frequency of their oral medication, how serious they
considered AF to be, how frequently they were concerned by stroke
risk, how much they wanted to be involved in OAC treatment deci-
sions, and which sources they used, if any, to obtain information
regarding their current OAC.
Patients were asked how familiar they were with standardized
information regarding AF, stroke, and the potential benefits and risks
of OACs (see Supporting Table 2 in the online version of this article).
2.1 | Ranking exercise
Before being exposed to the standardized information, patients
ranked by order of importance the following OAC attributes (which
were presented in a random order): stroke prevention, major bleeding
risk, other side effects, dosing frequency, antidote availability, dietary
restrictions, and whether medication needed to be taken with food.
2.2 | Choice-based conjoint analysis
After the standardized information had been presented, patients were
asked which of 3 hypothetical products they would be most willing to
take to prevent a stroke. Each product profile was characterized by
specific levels for 4 attributes: stroke risk reduction, major bleeding
risk, frequency of administration, and administration with/without
food (Figure 1) (see Supporting Table 3 in the online version of this
article). For each hypothetical product, stroke risk was either the same
as, or 21% or 36% lower than standard therapy; major bleeding risk
was either the same as, or 20% or 31% lower than standard therapy.
These figures were based on the results of the ARISTOTLE (Apixaban
for Reduction in Stroke and Other Thromboembolic Events in Atrial
Fibrillation Trial) and RE-LY (Randomized Evaluation of Long-Term
Anticoagulation Therapy) trials, where the rate of stroke was 21% and
36% lower with apixaban and dabigatran (150 mg), respectively, vs
warfarin, and the major bleeding rate was 31% and 20% lower with
apixaban and dabigatran (110 mg), respectively, vs warfarin.17–19 Each
hypothetical product was dosed once or twice daily and could be
taken with or without food.
Patients were asked to perform the hypothetical product selec-
tion a total of 10 times. The utility value of each characteristic was
determined using logistic regression based on a Bayesian analysis.
Points were awarded to each attribute level every time it appeared in
the patient's chosen hypothetical product profile (+1 if chosen, −1 if
not chosen, 0 if not presented), and each attribute level was given a
utility value.
Results were assessed for the overall study population and
according to AF subgroups, stroke knowledge, medication burden,
perceived seriousness of AF, and concern about stroke risk. Three
quality control assessments, increasing in stringency, were included to
ensure that patients gave considered answers rather than random
responses (see Supporting Table 4 in the online version of this article).
Descriptive statistics are presented as mean and standard devia-
tion (SD) for normally distributed continuous variables; categorical
data are presented as a number and percentage. Differences between
groups were compared using independent-sample t tests (means) and
χ2 tests (categorical data). P values comparing 3 or more subgroups
relate to data of 1 group vs other subgroups combined.
Informed consent was obtained from all participants. The survey
was conducted in accordance with the principles of the Declaration of
Helsinki.
3 | RESULTS
Between April 2015 and November 2015, 937 AF patients com-
pleted the survey from the United States (n = 322), Canada
(n = 145), Germany (n = 160), France (n = 171), and Japan (n = 139),
with an overall mean (SD) age of 54.3 (16.6) years; 37.1% were
female (Table 1). Of the 937 patients, 19.5%, 27.9%, and 29.8%
demonstrated good, moderate, and low levels of stroke knowledge,
respectively; 22.8% had no stroke knowledge. Stroke knowledge
was independent of educational level, and significantly lower in
those with AF and a recent stroke vs those with no recent stroke
(32.5% of patients with a recent stroke had no stroke knowledge vs
20.3% of those without a recent stroke).
The most commonly known stroke symptoms were numbness/
weakness/paralysis of the face, arm(s), leg(s) (known by 54.9% of
patients), followed by confusion or trouble speaking or understanding
speech (41.8%), dizziness (22.2%), trouble seeing/double vision
(15.4%), and severe headache with no known cause (14.8%). The most
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frequently mentioned stroke risk factors were high blood pressure/
hypertension (37.1%), smoking (26.8%), high cholesterol/hypercholes-
terolemia (19.7%), poor diet and/or lack of physical activity (17.4%),
and AF (17.4%) (see Supporting Figure 1 in the online version of this
article).
Familiarity with standardized information was stated to be good
in 39% of patients overall, in 37% of patients with recently diagnosed
AF without recent stroke, and in 53% of AF patients with a recent
stroke (see Supporting Table 5 in the online version of this article).
Significantly more patients with the lowest levels of education
(no school-leaving certificate) stated poor levels of familiarity with
standardized information (37% vs 11%–14% in other educational
groups).
Overall, 39.4% of patients (47.5% with good stroke knowledge)
perceived AF as extremely/very serious. Patients with good or moder-
ate stroke knowledge were more often concerned about a stroke than
those with no or low knowledge, who were more likely to never be
concerned about a stroke (Table 1). Better stroke knowledge was
associated with a preference for joint OAC treatment decision making
(Table 1) and with the use of more information sources about current
OACs and higher utilization of healthcare professionals' advice (see
Supporting Table 6 in the online version of this article).
Patients took a median of 3 different daily medications (interquar-
tile range, 2–6); 21.9% of patients took capsules/tablets once daily,
39.6% twice daily, and 38.5% ≥3 times daily.
3.1 | Ranking exercise
The attribute most often ranked as the most important was stroke
prevention (47.4% of patients), followed by major bleeding risk
(14.7%), other side effects (10.0%), dosing frequency (8.2%), antidote
availability (7.8), dietary restrictions (7.0%), and administration with/
without food (4.8%) (Figure 2). The proportions of patients who rated
TABLE 1 Patient characteristics, perceptions, and preferences
Stroke Knowledge
Conjoint
Analysis PatientsOverall Good Moderate Low None
No. (%) 937 (100) 183 (19.5) 261 (27.9) 279 (29.8) 214 (22.8) 676 (100)
Age, y, mean (SD) 54.3 (16.6) 60.7 (12.4)a 57.2 (15.0)a 53.9 (17.0) 45.7 (17.4)a 57.6 (15.5)
≥65 y, no. (%) 309 (33.0) 78 (42.6)a 104 (39.8)a 86 (30.8) 41 (19.2)a 268 (39.6)
Female, no. (%) 348 (37.1) 77 (42.1) 104 (39.8) 96 (34.4) 71 (33.2) 256 (37.9)
CHA2DS2-VASc score, mean (SD) 2.6 (1.7) 2.8 (1.8) 2.7 (1.7) 2.6 (1.7) 2.5 (1.5) 2.6 (1.7)
Educational level, %b
No school-leaving certificate 2.9 2.7 2.3 3.9 2.3 3.1
High school diploma 27.2 25.7 25.4 30.5 26.6 26.2
Community college 28.1 27.3 30.0 26.5 28.5 27.7
University/technical college 41.8 44.3 42.3 39.1 42.5 43.0
AF status, no. (%)
Newly diagnosed AF, no recent stroke 342 (36.5) 80 (43.7) 91 (34.9)a 99 (35.5) 72 (33.6) 265 (39.2)
Established AF, no recent stroke 401 (42.8) 84 (45.9) 117 (44.8) 121 (43.4) 79 (36.9)c 308 (45.6)
AF with recent stroke 194 (20.7) 19 (10.4)a 53 (20.3) 59 (21.1) 63 (29.4) 103 (15.2)
Perception of seriousness of AF, no. (%)
Extremely serious/very serious 369 (39.4) 87 (47.5)c 109 (41.8) 109 (39.1) 64 (29.9)a 268 (39.6)
Somewhat serious 390 (41.6) 76 (41.5) 110 (42.1) 113 (40.5) 91 (42.5) 282 (41.7)
Not at all/not serious 178 (19.0) 20 (10.9)a 42 (16.1) 57 (20.4) 59 (27.6)a 126 (18.6)
Concern about stroke, %
Often/always 43.4 44.8 46.0 40.5 43.0 38.9
Occasionally 45.4 50.3 46.0 45.2 40.7 61.1d
Never/I don't know 11.2 4.9 8.0 14.3 16.4 0
Patient preference for being involved in OAC treatment
choice, %
Doctor choice 44.7 26.8a 37.5a 50.5c 61.2a
Patient─doctor choice 35.6 51.9a 42.5a 32.3 17.8a
Patient choice 19.6 21.3 19.9 17.2 21.0
Abbreviations: AF, atrial fibrillation; OAC, oral anticoagulant; SD, standard deviation
a For stroke knowledge, P < 0.001 vs other groups pooled.
b Data from 936 patients.
c For stroke knowledge, P < 0.05 vs other groups pooled.
d Never/occasionally.
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stroke prevention as the most important attribute increased as stroke
knowledge improved (Figure 2).
3.2 | Conjoint analysis
All 937 patients completed a choice-based conjoint analysis; however,
answers from 261 patients did not meet the quality assessments and
were excluded, leaving 676 patients (232 in the United States, 104 in
Canada, 94 in Japan, 123 in France, and 123 in Germany) (see Sup-
porting Figure 2 in the online version of this article). Baseline charac-
teristics are presented in Table 1.
Overall, patients valued stroke risk reduction as the most impor-
tant OAC attribute, followed by major bleeding risk, frequency of
administration, and administration with/without food, with utility
values of 194.3, 115.9, 32.0, and 29.8, respectively. A 21% reduction
in stroke risk vs standard therapy brings 77.5 points of utility, whereas
a 20% reduction in major bleeding risk vs standard therapy results in
83.6 points of utility (Figure 3).
Stroke prevention was the most important attribute indepen-
dent of stroke knowledge and was valued more highly in patients
with better levels of stroke knowledge vs. those with lower levels
of/no stroke knowledge (Figure 4). The relative level of importance
placed on the 4 attributes was consistent across patient groups,
regardless of their predefined AF subgroup, perceived seriousness
of AF, concern about stroke, and the frequency that they took oral
medication (see Supporting Figures 3–6 in the online version of this
article).
4 | DISCUSSION
To our knowledge, this is the largest published study to assess OAC
preferences among AF patients and is highly relevant to contemporary
clinical practice, because patient values are increasingly featured in AF
management guidelines.1–3,20,21 OAC attributes relating to efficacy
and safety were considered the most important in the ranking exer-
cise and conjoint analysis, regardless of the AF subgroup, level of
stroke knowledge, perception of seriousness of AF, concern about
stroke, and the frequency of administration.
Unlike some previous surveys,10,14 our study assessed stroke
knowledge using open-ended questions, which may more accurately
reflect a patient's level of understanding; asking patients to select
FIGURE 1 Example of a display of hypothetical product profiles presented to patients
FIGURE 2 Oral anticoagulation attributes rated most important in
ranking exercise. † indicates p<0.001 vs other groups pooled.
* indicated p<0.05 vs other groups pooled
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from a list of potential answers may bias results. Patients with a recent
stroke had significantly lower levels of stroke knowledge than those
with no recent stroke, even though recent stroke patients claimed to
be highly familiar with the standardized information. Those with a
recent stroke may have moderate disability or residual cognitive
impairment,22–24 which could limit their ability to enter free text or
recall answers unaided in response to open-ended questions. Patients
with recent stroke experience may also find it more challenging to
confront risk factors associated with the condition and devote less
time to open-ended questions.
Better stroke knowledge was associated with using more infor-
mation sources regarding current OACs, increased use of advice from
FIGURE 3 Relative gain in utility values determined from conjoint analysis. Abbreviations: BID, twice a day; OD, once a day
FIGURE 4 Relative gain in utility values according to stroke knowledge
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healthcare professionals, and a preference for joint OAC treatment
decision making. Poor stroke knowledge was common and indepen-
dent of educational level. Only 17.4% of patients named AF as a
stroke risk factor, even though all respondents had AF. These findings
highlight the need for improved healthcare professional–patient
dialogue.
Preexisting stroke knowledge did not affect the order in which
OAC attributes were ranked in the ranking exercise or valued in the
conjoint exercise, which were consistent. Information from a ranking
exercise may be limited, as patients are likely to desire all of the bene-
fits at no cost. Assessing patient-perceived values through a conjoint
exercise forces patients into making a trade-off between positive and
negative attributes, more accurately reflecting real life, where 1 treat-
ment is selected over others based on its individual profile.25 Stan-
dardized information regarding AF, stroke, and OACs was presented
before the conjoint analysis, so that stroke knowledge was more con-
sistent across the study population.
Our findings are consistent with those from other studies, in which
efficacy and safety have been rated highly by patients.6,26–28 Recent
systematic reviews focusing on OAC preferences in AF patients showed
that most patients valued stroke prevention over other attributes.25,29
In a study by Lahaye et al., newly diagnosed AF patients were willing to
suffer 4.4 major bleeds to prevent 1 stroke, demonstrating the impor-
tance placed on efficacy. However, 12% of patients in the study were
unwilling to take antithrombotic therapy even if it was 100% effec-
tive.28 Of note, our study only included patients taking an OAC with an
AF diagnosis dating back as far as 3 years; those unwilling to take
antithrombotic treatment were excluded.
Although AF patients considered stroke risk reduction to be the
most important OAC attribute in our study, an improvement of 21%
over standard therapy appeared to be less compelling than a 20%
reduction in major bleeding risk.
Our study is unusual in that we explored the potential impact of
stroke knowledge and previous stroke on patient preferences regard-
ing OAC attributes. The value placed on each attribute was consistent
across all subgroups evaluated, including stroke knowledge and stroke
history. Interestingly, frequency of administration was of minor impor-
tance, regardless of the number of times per day that patients took
oral medication.
The attributes evaluated in the conjoint analysis were chosen
because each had a manageable number of permutations and could
be used to differentiate the currently available new oral anticoagu-
lants (NOACs). Dabigatran and apixaban are administered twice daily;
edoxaban and rivaroxaban are dosed once daily, and unlike the other
NOACs, rivaroxaban must be taken with food. Dabigatran is the only
available NOAC for which a specific reversal agent (idarucizumab) is
available. However, as the survey was conducted largely before its
introduction, reversal agent availability was not included as an
attribute.
Previous conjoint analyses or discrete choice experiments focus-
ing on OACs generally included modest patient numbers and were not
always limited to patients eligible for an OAC.27,30 In addition, some
have excluded efficacy and/or safety attributes, and consequently,
findings may imply that patients place greater importance on
convenience factors such as dosing frequency.31,32 The results of our
analysis suggest that stroke prevention and major bleeding risk are by
far the most important factors that concern patients when selecting
an OAC.
4.1 | Study limitations
This study has certain limitations. Online methodology may have
introduced bias toward younger patients, males, and those with a
higher educational level; however, preferences for OAC attributes
were independent of age, sex, and educational level (data not shown).
In addition, the survey reflects the views of AF patients taking OACs,
whereas in clinical practice, a considerable proportion of patients are
not treated with OACs despite a clear indication.33,34
5 | CONCLUSION
The findings of our study suggest that efficacy and safety are consid-
ered to be the most important OAC attributes by the majority of AF
patients. Dosing frequency was found to be of minor importance to
most AF patients, irrespective of stroke knowledge, medication bur-
den, perception of seriousness of AF, or concern about stroke. Under-
standing patients' needs and preferences with regard to OAC
treatment will improve clinical outcomes, and as such we believe that
our findings should be considered when discussing and selecting
OACs with AF patients.
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